World-renowned physician, Dr. Michael Roizen, MD, continues to update your understanding of the meaning of health by providing an in-depth review of the most impactful health headlines.
Joined by his co-host, Joe Galuski, they discuss the health news that matters most to you.
The duo is later joined by Dr. Ronan Kelly. Dr. Kelly is a thoracic oncologist at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and is leading translational research efforts in esophageal, gastro-esophageal and gastric cancer. He just authored an interesting study on ways to cut costs in cancer treatment without hurting patient care.
Dr. Kelly is also a board member with ECAN (Esophageal Cancer Action Network). You can visit the ECAN website at www.ECAN.org.
Bonus!
Real Age Tip
Top 10 Stressed-Out Cities
Hour 1: YOU The Owner's Manual Radio 5.3.14
Featuring:
His research involves utilizing epigenetic changes as biomarkers to better predict which chemotherapies patients should receive in both the operable and metastatic setting. In addition, he is evaluating novel targeted agents and is incorporating immunotherapeutic and epigenetic modifying agents in upper GI tumors.
Dr. Kelly chairs the Johns Hopkins esophageal and gastric cancer working groups and is a prominent member of the Eastern Cooperative Oncology Groups gastro-esophageal cancer task force. In addition to academic research in upper GI tumors, Dr. Kelly is actively involved in designing pathways and implementing strategic developments to decrease cancer costs while improving efficacy both nationally and internationally. He is an ECAN (Esophageal Cancer Action Network) board member and he just authored an interesting study on ways to cut costs in cancer treatment without hurting patient care.
Ronan Kelly, MD
Dr. Ronan Kelly, MD, MBA, heads Medical Oncology for Esophageal Cancer at Johns Hopkins Medicine, as well as the Johns Hopkins International Oncology program. Dr. Kelly is a thoracic oncologist at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and is leading translational research efforts in esophageal, gastro-esophageal and gastric cancer.His research involves utilizing epigenetic changes as biomarkers to better predict which chemotherapies patients should receive in both the operable and metastatic setting. In addition, he is evaluating novel targeted agents and is incorporating immunotherapeutic and epigenetic modifying agents in upper GI tumors.
Dr. Kelly chairs the Johns Hopkins esophageal and gastric cancer working groups and is a prominent member of the Eastern Cooperative Oncology Groups gastro-esophageal cancer task force. In addition to academic research in upper GI tumors, Dr. Kelly is actively involved in designing pathways and implementing strategic developments to decrease cancer costs while improving efficacy both nationally and internationally. He is an ECAN (Esophageal Cancer Action Network) board member and he just authored an interesting study on ways to cut costs in cancer treatment without hurting patient care.